| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | Crizotinib | CCLE | pan-cancer | AAC | -0.0024 | 1 |
| mRNA | CAY10594 | CTRPv2 | pan-cancer | AAC | -0.002 | 1 |
| mRNA | XMD15-27 | GDSC1000 | pan-cancer | AAC | -0.0018 | 1 |
| mRNA | GNF-2 | GDSC1000 | pan-cancer | AAC | -0.0029 | 1 |
| mRNA | BRD-A02303741 | CTRPv2 | pan-cancer | AAC | -0.002 | 1 |
| mRNA | 17-AAG | CCLE | pan-cancer | AAC | 0.0022 | 1 |
| mRNA | tipifarnib | CTRPv2 | pan-cancer | AAC | 0.0013 | 1 |
| mRNA | Vandetanib | CCLE | pan-cancer | AAC | -0.0019 | 1 |
| mRNA | ATRA | CTRPv2 | pan-cancer | AAC | -0.0015 | 1 |
| mRNA | BRD8899 | CTRPv2 | pan-cancer | AAC | -0.0016 | 1 |